Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 16/20 | 0.43 |
| ▸ | AURKA | O14965 | 12/20 | 0.43 |
| ▸ | AKT1 | P31749 | 4/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.42 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527275 | 0.92 | RPS6KB1 (0.53) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL527124 | 0.76 | RPS6KB1 (0.40) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL15054872 | 0.75 | RPS6KB1 (0.40) | RPS6KB1AURKA | |
| SCHEMBL15054871 | 0.75 | RPS6KB1 (0.40) | RPS6KB1AURKA | |
| SCHEMBL666154 | 0.73 | RPS6KB1 (0.54) | RPS6KB1AURKAAURKB | |
| SCHEMBL14974538 | 0.70 | RPS6KB1 (0.47) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL28137529 | 0.68 | RPS6KB1 (0.42) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL14974401 | 0.67 | RPS6KB1 (0.82) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL12467154 | 0.67 | KMT2A (0.48) | — | |
| Trifluoroacetic Acid SCHEMBL14974697 | 0.67 | POLB (0.34) | RPS6KB1AURKAAKT1AURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598492-B1 | BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K | MERCK PATENT GMBH (DE) | 2015-10-28 | — | — | EP | disclosed |
| US-8710044-B2 | Bicyclic azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-2598492-A1 | BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K | Merck Patent GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137677-A1 | Bicyclic Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| WO-2012013282-A1 | BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K | MERCK PATENT GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137677-A1 | Bicyclic Azaheterocyclic Carboxamides | CCNI, CCNA1, CCNA2 | RPS6KB1 731/4885AURKA 523/4885AKT1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.